Skip to main content
Terug
Watch Compare

Anebulo Pharmaceuticals, Inc.

Datakwaliteit: 83%
ANEB
OTC Manufacturing Chemicals
€ 0,54
▼ € 0,04 (-7,24%)
Marktkapitalisatie: 24,51 M
Prijs
€ 0,60
Marktkapitalisatie
24,51 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Negative free cash flow of -5,84 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-90,29%
Onder sectorgemiddelde (-54,01%)
ROIC-71,48%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current RatioN/A
Interest Coverage-28,84

Waardering

PE (TTM)
-3,07
Onder sectorgemiddelde (-1,49)
P/B Ratio3,09
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1385 peers)
Metriek Aandeel Sector Mediaan
P/E -3,1 -1,5
P/B 3,1 1,6
ROE % -90,3 -54,0
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

Koersdoel Analisten

1 analist
Geen analistendekking beschikbaar

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2026 — 0,0 —

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q32025 -€ 0,12 -€ 0,05 +58,3%
Q22025 -€ 0,05 -€ 0,05 0,0%
Q12025 -€ 0,05 -€ 0,04 +20,0%
Q42024 -€ 0,08 -€ 0,09 -12,5%

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -7,98 M
ROE -90,29% ROA -79,30%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -5,84 M
ROIC -71,48% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio N/A
Interest Coverage -28,84 Asset Turnover N/A
Working Capital N/A Tangible Book Value 7,94 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -3,07 Forward P/E N/A
P/B Ratio 3,09 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -23,83%
Market Cap 24,51 M Enterprise Value 15,47 M
Per Share
EPS (Diluted TTM) -0,18 Revenue / Share N/A
FCF / Share -0,14 OCF / Share -0,14
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 73,20%
SBC-Adj. FCF -6,82 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2021 FY2022
Revenue — — — — —
Net Income -8,48 M -8,20 M -11,73 M -30,25 M -6,83 M
EPS (Diluted) -0,25 -0,32 0,47 — —
Gross Profit — — — — —
Operating Income -9,22 M -8,31 M -11,78 M — -6,83 M
EBITDA — — — — —
R&D Expenses 4,30 M 3,55 M 5,60 M 2,27 M 2,96 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense 400.000,0 151.230,0 — 11.767,0 11.767,0
Income Tax — — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2021 FY2022
Total Assets 12,15 M 4,07 M 11,67 M 21,65 M 15,58 M
Total Liabilities 487.688,0 260.583,0 1,07 M 241.633,0 512.531,0
Shareholders' Equity 11,66 M 3,81 M 10,60 M 21,41 M 15,07 M
Total Debt — — — — —
Cash & Equivalents 11,63 M 3,09 M — — —
Current Assets 11,96 M 3,51 M — — —
Current Liabilities — — — — —